BRAF-targeted therapy and immune responses to melanoma

Oncoimmunology. 2013 Jun 1;2(6):e24462. doi: 10.4161/onci.24462. Epub 2013 May 9.

Abstract

Type I BRAF inhibitors and immunotherapy constitute two new exciting approaches for the treatment of advanced malignant melanoma. We have recently elucidated a role for host C-C chemokine receptor type 2 (CCR2) in the antineoplastic effects of type I BRAF inhibitors in mice, supporting the therapeutic potential of combining BRAF inhibitors with immunotherapy.

Keywords: BRAF; T cell; checkpoint; immunity; melanoma.